Wiener J S, Coppes M J, Ritchey M L
Scott Department of Urology, Baylor College of Medicine, Houston, Texas, USA.
J Urol. 1998 Apr;159(4):1316-25.
There have been a number of advances that have increased our understanding of the biology of Wilms tumor during the last decade. This information is now being incorporated into current pediatric oncology protocols. We present a summary of these advances and outline the current treatment of Wilms tumor.
The medical literature was reviewed with an emphasis on the molecular biology of Wilms tumor.
The development of Wilms tumor involves several genes, including WT1, the Wilms tumor suppressor gene at 11p13. In addition, certain chromosomal regions (16q and 1p) might be used as prognostic factors for determining the intensity of therapy.
Future protocols conducted by pediatric oncology groups will incorporate biological studies. The goal is to identify patients at low risk for relapse which will allow a reduction in treatment intensity and subsequent toxicity. Children at an increased risk for relapse can be selected for more intensive treatment.
在过去十年中，出现了许多进展，加深了我们对肾母细胞瘤生物学特性的理解。这些信息目前正被纳入当前的儿科肿瘤学治疗方案中。我们总结这些进展，并概述肾母细胞瘤的当前治疗方法。
回顾医学文献，重点关注肾母细胞瘤的分子生物学。
肾母细胞瘤的发生涉及多个基因，包括位于11p13的肾母细胞瘤抑制基因WT1。此外，某些染色体区域（16q和1p）可作为判断治疗强度的预后因素。
儿科肿瘤学小组开展的未来治疗方案将纳入生物学研究。目标是识别复发风险低的患者，从而降低治疗强度及后续毒性。复发风险增加的儿童可选择更强化的治疗。
